Transcutaneous Photodynamic Therapy Alters the Development of an Adoptively Transferred Form of Murine Experimental Autoimmune Encephalomyelitis

Abstract— Transcutaneous photodynamic therapy (PDT), utilizing benzoporphyrin derivative monoacid ring A (BPD, ver‐teporfin) and whole‐body light exposure, was assessed for its capacity to modify the course of adoptively transferred experimental autoimmune encephalomyelitis (EAE) in PL mice. Using a novel cell culture technique to facilitate the induction of this neurodegenerative condition, disease signs commenced 3–4 weeks after the transfer of myelin basic protein (MBP)‐reactive lymph node or spleen cells to naive syngeneic recipients. Mice administered MBP‐sensitized lymph node cells preincu‐bated with BPD followed by whole‐body 690 nm light irradiation (15 J/cm2) did not display symptoms of EAE. Although almost all animals given MBP‐sensitized spleen cells developed EAE, mice given BPD (1 mg/kg) and the light treatment 24, 48 or 120 h after spleen cell transfer exhibited significantly less severe disease symptoms than control animals. Mice given the photodynamic treatment 24 h after spleen cell transfer also exhibited a significantly later disease onset than the control animals. Treatment of mice with PDT 24 h prior to spleen cell transfer did not influence subsequent disease severity but modestly delayed its onset. In the absence of directed light, BPD did not influence the development of EAE. Spinal cord tissues were evaluated for the presence of T cell receptor (TCR) Vα4 mRNA transcripts that specifically encode for the TCR ot‐chain of MBP‐reactive T cells of PL mice. Using the polymerase chain reaction, Va4 TCR mRNA transcripts were present in spinal cord samples prepared from almost all control mice but in only about one‐half of spinal cord samples prepared from mice treated with PDT 24 h after spleen cell transfer. These observations indicated that PDT had limited the expansion of MBP‐specific Vot4+ T cells within the central nervous system. Transcutaneous PDT represents a new technique with which to approach the treatment of autoimmune disease.